78998
document
[ Treatment of essential headache in developmental age with L-5-HTP ( cross over double-blind study versus placebo ) ] . Thirty patients ( mean age : 10.38 years ) affected by primary headache were selected for a double-blind cross-over clinical trial . The patients were randomized into 2 homogeneous groups of 15 and treated for 12 weeks with L-5-HTP ( 100 mg/day ) and placebo as per the following design : placebo - L-5-HTP ( group A ) and L-5-HTP - placebo ( group B ) . Evaluation was carried out every 3 weeks by the Migraine Index supplying a general assessment of the attacks , i.e . severity , duration and frequency . The decrease in mean score values was directly proportional to L-5-HTP treatment , and statistical significance ( Wilcoxon 's test ) was observed only for L-5-HTP in both groups , from 0.05 to 0.01 . Improvement , as evaluated by CGI on percentage distribution of the patients , was homogeneous in both groups .
78999
Intervention_Physical
L-5-HTP
79000
Intervention_Control
placebo
79001
Intervention_Pharmacological
L-5-HTP
79002
Intervention_Control
placebo
79003
Intervention_Control
placebo
79004
Intervention_Pharmacological
L-5-HTP
79005
Intervention_Pharmacological
L-5-HTP
79006
Intervention_Control
placebo
79007
Intervention_Physical
L-5-HTP
79008
Outcome_Physical
essential headache
79009
Outcome_Physical
primary headache
79010
Outcome_Other
Migraine Index
79011
Outcome_Other
general assessment of the attacks
79012
Outcome_Physical
severity
79013
Outcome_Physical
duration
79014
Outcome_Other
frequency
79015
Outcome_Other
mean score values
79016
Outcome_Other
Wilcoxon 's test
79017
Participant_Condition
developmental age
79018
Participant_Condition
Thirty patients ( mean age : 10.38 years ) affected by primary headache were selected